Skip to main content
OpenTrials

Clinical trial condition

Refractory Hodgkin Lymphoma

Explore clinical trials studying Refractory Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

34 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Refractory Hodgkin Lymphoma trial results

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
View Trial Details
Recruiting

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

NCT06487624

Conditions
Advanced Solid Tumor, Bone Diseases, Bone Diseases, Developmental, +15 more
Locations
  • Prisma Health-Upstate Greenville, South Carolina, United States
  • The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China
  • Zhejiang Provincial Cancer Hospital Hangzhou, China
  • Xuzhou Central Hospital Xuzhou, China
View Trial Details
Not yet recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

NCT07021989

Conditions
Classic Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +9 more
Locations
  • University of California Davis Davis, California, United States
  • University of California San Francisco-Fresno Fresno, California, United States
  • University of California Irvine Irvine, California, United States
  • University of California, San Diego La Jolla, California, United States
View Trial Details
Active, not recruiting

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

NCT03016871

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
View Trial Details
Active, not recruiting

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

NCT03057795

Conditions
Classic Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +9 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details

Related conditions